Skip to content
Company Analysis

Novo Nordisk A/S NVO

A comprehensive view of key metrics, scores, and financial health for Novo Nordisk A/S

Overview of Novo Nordisk A/S

NVO NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Large Cap
Novo Nordisk A/S (NVO), is a Large Cap company, in the Drug Manufacturers - General industry, last closed at $40.45, about 32.7% overvalued vs fair value, -13.0% 1Y return, ranked 628/1145 in sector.
Metrics P/E 14.0× Rev Growth 6.4% ROE 60.7% Gross Margin 81.0% Div Yield 3.60%
USD 40.45
1.13%
(Delayed)
• Vol 90d: 35.1%
52-Week Range
Market Cap
$178.73B
Enterprise Value
$193.12B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Good
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 100%
Confidence: 97%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.novonordisk.com
HQ Bagsvaerd
Employees 68,794
Fiscal year Dec 31

Next Events

Earnings Nov 4 Call: Nov 4

Fair Value Snapshot

Bear Base Bull
$25
$27
$29
Current: $40.45 -33% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
DKK 309.1B
6.4%%
Gross Profit
DKK 250.3B
1.8%%
R&D Expense
DKK 52.0B
8.3%%
Operating Income (EBIT)
DKK 134.7B
4.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
88.4%
Good

Good cash conversion

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

DKK 53.2B
183.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
0/3
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Novo Nordisk A/S's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
74
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Consistently Above Peers Gross margin at 81.0% (top 11%) and operating margin at 41.3% (top 0%) indicate strong pricing power.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.94), demonstrating pricing resilience across cycles.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.21), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
94
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing NVO's balance between Growth (30.4%), Profitability (46.8%), and Safety (22.9%). Growth 30% Safety 23% Profitability 47%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

59th percentile vs peers
59
Key Signals
Revenue CAGR 3Y 20.4% 82p Rev Growth YoY 6.4% 59p EPS CAGR 3Y 23.5% 77p EPS Growth YoY 1.8% 31p TSR -38.7% 27p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (20.4%, 82th percentile)
  • Interest Coverage Ratio in top 20% of peers (32.03, 96th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Operating Margin in top 20% of peers (41.3%, 98th percentile)
Risks

No significant risks identified for this axis.

Profitability

90th percentile vs peers
91
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

44th percentile vs peers
44
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Novo Nordisk A/S.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$27.24
- - -
-32.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000